Rebecca L. Dekker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca L. Dekker has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Debra K. Moser
University of Kentucky College of Nursing, Lexington, KY, USA
5 shared publicationsTerry A. Lennie
University of Kentucky College of Nursing, Lexington, KY, USA
5 shared publicationsAnn R. Peden
†Capital University Department of Nursing
3 shared publicationsMisook L. Chung
University of Kentucky College of Nursing, Lexington, KY, USA
3 shared publicationsChristine H. Morton
2 shared publicationsDebra K Moser
College of Nursing, University of Kentucky, USA
2 shared publications
Latest Publications
- 20 September 2016
- Published by SAGE Publications in Biological Research For Nursing
- Vol. 19 (2) , 153-161
Salivary Biomarkers, Oral Inflammation, and Functional Status in Patients With Heart Failure
Aims: To describe correlations and agreement between salivary and serum B-type natriuretic peptide (BNP), C-reactive protein (CRP), interleukin (IL)-6, and IL-10 and determine which biomarkers predict worse functional class in patients with heart failure (HF). Methods: Serum and saliva were collected from 75 hospitalized patients with HF (57 ± 12 years, 43% female, New York Heart Association [NYHA] Classes I [4%], II [43%], and III [53%]). Oral inflammation was rated as good, fair, or poor. Spearman’s ρ and Bland–Altman were used to determine correlations and agreement of the salivary and serum forms of each biomarker. Logistic regressions were used to determine which biomarkers predicted worse NYHA functional class, controlling for depression, body mass index, smoking, and oral inflammation. Results: Median biomarker concentrations were as follows: BNP (serum 361 pg/ml, saliva 9 pg/ml), CRP (serum 13 ng/ml, saliva 25.6 ng/ml), IL-6 (serum 19.3 pg/ml, saliva 10.5 pg/ml), and IL-10 (serum 64.1 pg/ml, saliva 4.7 pg/ml). There was a moderate-to-strong correlation for serum–salivary CRP, weak correlation for serum–salivary IL-6, and no correlations for serum–salivary BNP and IL-10. The Bland–Altman test showed good salivary–serum agreement for all biomarkers, but as serum concentrations rose, salivary measures underestimated serum levels. Visible oral inflammation was the only predictor of worse NYHA class.
- 20 September 2016
- Published by SAGE Publications in Biological Research For Nursing
- Vol. 19 (2) , 153-161
Salivary Biomarkers, Oral Inflammation, and Functional Status in Patients With Heart Failure
Aims: To describe correlations and agreement between salivary and serum B-type natriuretic peptide (BNP), C-reactive protein (CRP), interleukin (IL)-6, and IL-10 and determine which biomarkers predict worse functional class in patients with heart failure (HF). Methods: Serum and saliva were collected from 75 hospitalized patients with HF (57 ± 12 years, 43% female, New York Heart Association [NYHA] Classes I [4%], II [43%], and III [53%]). Oral inflammation was rated as good, fair, or poor. Spearman’s ρ and Bland–Altman were used to determine correlations and agreement of the salivary and serum forms of each biomarker. Logistic regressions were used to determine which biomarkers predicted worse NYHA functional class, controlling for depression, body mass index, smoking, and oral inflammation. Results: Median biomarker concentrations were as follows: BNP (serum 361 pg/ml, saliva 9 pg/ml), CRP (serum 13 ng/ml, saliva 25.6 ng/ml), IL-6 (serum 19.3 pg/ml, saliva 10.5 pg/ml), and IL-10 (serum 64.1 pg/ml, saliva 4.7 pg/ml). There was a moderate-to-strong correlation for serum–salivary CRP, weak correlation for serum–salivary IL-6, and no correlations for serum–salivary BNP and IL-10. The Bland–Altman test showed good salivary–serum agreement for all biomarkers, but as serum concentrations rose, salivary measures underestimated serum levels. Visible oral inflammation was the only predictor of worse NYHA class.
- 10 June 2016
- Published by Wiley in Journal of Midwifery & Women's Health
- Vol. 61 (4) , 467-473
Women's Experiences Being Diagnosed With Peripartum Cardiomyopathy: A Qualitative Study
Introduction: Cardiovascular disease has been identified as the leading cause of maternal mortality in the United States, with cardiomyopathy, including peripartum cardiomyopathy (PPCM), accounting for 12% to 16% of all pregnancy‐related deaths. The purpose of this study was to describe women's experiences being diagnosed with PPCM.Methods: This investigation was conducted using a qualitative design. We collected publicly available narratives posted by 92 women with PPCM (mean [SD] age 29 [6] years, mean [SD] ejection fraction 25.5 [10.8]%) in 3 online support groups. Data were coded and thematically organized so as to produce a richly detailed account of this experience.Results: The experience of diagnosis was marked by the women's distinct memories of their initial symptoms and whether they were dismissed or taken seriously. The most commonly reported symptoms were extreme shortness of breath, orthopnea, tachycardia, palpitations, chest pain, cough, and edema. Nearly 40% of women experienced symptom dismissal by health care providers. One‐fourth of women were initially given inaccurate diagnoses ranging from “new mom anxiety” to asthma. Women described their initial reaction to diagnosis as feeling terrified, devastated, and feeling a sense of doom. Women had difficulty caring for their newborns during the postpartum period, and they struggled with the medical advice they received to not get pregnant again.Discussion: Despite experiencing severe subjective and objective symptoms, nearly 40% of women with PPCM experienced symptom dismissal by health care providers, in part due to the overlap between normal symptoms of pregnancy or the postpartum period and symptoms of heart failure.
- 10 June 2016
- Published by Wiley in Journal of Midwifery & Women's Health
- Vol. 61 (4) , 467-473
Women's Experiences Being Diagnosed With Peripartum Cardiomyopathy: A Qualitative Study
Introduction: Cardiovascular disease has been identified as the leading cause of maternal mortality in the United States, with cardiomyopathy, including peripartum cardiomyopathy (PPCM), accounting for 12% to 16% of all pregnancy‐related deaths. The purpose of this study was to describe women's experiences being diagnosed with PPCM.Methods: This investigation was conducted using a qualitative design. We collected publicly available narratives posted by 92 women with PPCM (mean [SD] age 29 [6] years, mean [SD] ejection fraction 25.5 [10.8]%) in 3 online support groups. Data were coded and thematically organized so as to produce a richly detailed account of this experience.Results: The experience of diagnosis was marked by the women's distinct memories of their initial symptoms and whether they were dismissed or taken seriously. The most commonly reported symptoms were extreme shortness of breath, orthopnea, tachycardia, palpitations, chest pain, cough, and edema. Nearly 40% of women experienced symptom dismissal by health care providers. One‐fourth of women were initially given inaccurate diagnoses ranging from “new mom anxiety” to asthma. Women described their initial reaction to diagnosis as feeling terrified, devastated, and feeling a sense of doom. Women had difficulty caring for their newborns during the postpartum period, and they struggled with the medical advice they received to not get pregnant again.Discussion: Despite experiencing severe subjective and objective symptoms, nearly 40% of women with PPCM experienced symptom dismissal by health care providers, in part due to the overlap between normal symptoms of pregnancy or the postpartum period and symptoms of heart failure.
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S6
Women's Experiences Being Diagnosed with Peripartum Cardiomyopathy
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S6
Women's Experiences Being Diagnosed with Peripartum Cardiomyopathy
- 9 January 2014
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 13 (2) , 168-176
Coexisting anxiety and depressive symptoms in patients with heart failure
Among patients with heart failure (HF), anxiety symptoms may co-exist with depressive symptoms. However, the extent of overlap and risk factors for anxiety symptoms have not been thoroughly described. The aim of this study was to describe the coexistence of anxiety and depressive symptoms, and to determine the predictors of anxiety symptoms in patients with HF. The sample consisted of 556 outpatients with HF (34% female, 62±12 years, 54% New York Heart Association (NYHA) class III/IV) enrolled in a multicenter HF quality of life registry. Anxiety symptoms were assessed with the Brief Symptom Inventory-anxiety subscale. Depressive symptoms were measured with the Beck Depression Inventory-II (BDI). We used a cut-point of 0.35 to categorize patients as having anxiety symptoms or no anxiety symptoms. Logistic regression was used to determine whether age, gender, minority status, educational level, functional status, comorbidities, depressive symptoms, and antidepressant use were predictors of anxiety symptoms. One-third of patients had both depressive and anxiety symptoms. There was a dose-response relationship between depressive symptoms and anxiety symptoms; higher levels of depressive symptoms were associated with a higher level of anxiety symptoms. Younger age (odds ratio (OR)= 0.97, p=0.004, 95% confidence interval (CI) 0.95–0.99) and depressive symptoms (OR =1.25, p<0.001, 95% CI 1.19–1.31) were independent predictors of anxiety symptoms. Patients with HF and depressive symptoms are at high risk for experiencing anxiety symptoms. Clinicians should assess these patients for comorbid anxiety symptoms. Research is needed to test interventions for both depressive and anxiety symptoms.
- 9 January 2014
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 13 (2) , 168-176
Coexisting anxiety and depressive symptoms in patients with heart failure
Among patients with heart failure (HF), anxiety symptoms may co-exist with depressive symptoms. However, the extent of overlap and risk factors for anxiety symptoms have not been thoroughly described. The aim of this study was to describe the coexistence of anxiety and depressive symptoms, and to determine the predictors of anxiety symptoms in patients with HF. The sample consisted of 556 outpatients with HF (34% female, 62±12 years, 54% New York Heart Association (NYHA) class III/IV) enrolled in a multicenter HF quality of life registry. Anxiety symptoms were assessed with the Brief Symptom Inventory-anxiety subscale. Depressive symptoms were measured with the Beck Depression Inventory-II (BDI). We used a cut-point of 0.35 to categorize patients as having anxiety symptoms or no anxiety symptoms. Logistic regression was used to determine whether age, gender, minority status, educational level, functional status, comorbidities, depressive symptoms, and antidepressant use were predictors of anxiety symptoms. One-third of patients had both depressive and anxiety symptoms. There was a dose-response relationship between depressive symptoms and anxiety symptoms; higher levels of depressive symptoms were associated with a higher level of anxiety symptoms. Younger age (odds ratio (OR)= 0.97, p=0.004, 95% confidence interval (CI) 0.95–0.99) and depressive symptoms (OR =1.25, p<0.001, 95% CI 1.19–1.31) were independent predictors of anxiety symptoms. Patients with HF and depressive symptoms are at high risk for experiencing anxiety symptoms. Clinicians should assess these patients for comorbid anxiety symptoms. Research is needed to test interventions for both depressive and anxiety symptoms.
- 23 September 2013
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 13 (5) , 444-450
Depressive symptoms and inflammatory biomarkers in patients with heart failure
Inflammation may be a link between depressive symptoms and outcomes in patients with heart failure. It is not clear whether inflammatory markers are independently related to depressive symptoms in this population. To determine which inflammatory biomarkers are independently associated with depressive symptoms in heart failure. We analyzed data from 428 outpatients enrolled in a heart failure registry (32% female, 61 ± 12 years, 48% New York Heart Association Class III/IV). Depressive symptoms were measured with the Beck Depression Inventory-II. Serum C-reactive protein (CRP), cytokines (interleukin 1 receptor antagonist, 2, 4, 6, 8, 10), tumor necrosis alpha, and soluble receptors sTNFR1 and sTNFR2 were measured with enzyme immunoassay. Multiple regressions were used to determine which biomarkers were associated with depressive symptoms controlling for demographics, heart failure severity, and clinical variables. Twenty-seven percent (n = 119) had depressive symptoms. CRP was related to depressive symptoms after controlling for age and gender, but no inflammatory biomarkers were associated with depressive symptoms after controlling for all variables in the model. There was no relationship between inflammatory biomarkers and depressive symptoms. Our findings, in combination with prior researchers’, suggest there is not a robust relationship between depressive symptoms and individual biomarkers of inflammation in heart failure.
- 23 September 2013
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 13 (5) , 444-450
Depressive symptoms and inflammatory biomarkers in patients with heart failure
Inflammation may be a link between depressive symptoms and outcomes in patients with heart failure. It is not clear whether inflammatory markers are independently related to depressive symptoms in this population. To determine which inflammatory biomarkers are independently associated with depressive symptoms in heart failure. We analyzed data from 428 outpatients enrolled in a heart failure registry (32% female, 61 ± 12 years, 48% New York Heart Association Class III/IV). Depressive symptoms were measured with the Beck Depression Inventory-II. Serum C-reactive protein (CRP), cytokines (interleukin 1 receptor antagonist, 2, 4, 6, 8, 10), tumor necrosis alpha, and soluble receptors sTNFR1 and sTNFR2 were measured with enzyme immunoassay. Multiple regressions were used to determine which biomarkers were associated with depressive symptoms controlling for demographics, heart failure severity, and clinical variables. Twenty-seven percent (n = 119) had depressive symptoms. CRP was related to depressive symptoms after controlling for age and gender, but no inflammatory biomarkers were associated with depressive symptoms after controlling for all variables in the model. There was no relationship between inflammatory biomarkers and depressive symptoms. Our findings, in combination with prior researchers’, suggest there is not a robust relationship between depressive symptoms and individual biomarkers of inflammation in heart failure.
- 1 January 2012
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 18 (1) , 10-20
Cognitive Therapy Improves Three-Month Outcomes in Hospitalized Patients With Heart Failure
- 1 January 2012
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 18 (1) , 10-20
Cognitive Therapy Improves Three-Month Outcomes in Hospitalized Patients With Heart Failure
- 1 September 2011
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 17 (9) , 755-763
Depressive Symptom Trajectory Predicts 1-Year Health-Related Quality of Life in Patients With Heart Failure
- 1 September 2011
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 17 (9) , 755-763
Depressive Symptom Trajectory Predicts 1-Year Health-Related Quality of Life in Patients With Heart Failure
- 1 May 2011
- Published by Elsevier in Heart & Lung
- Vol. 40 (3) , e60-e69
Developing a shortened measure of negative thinking for use in patients with heart failure
- 1 May 2011
- Published by Elsevier in Heart & Lung
- Vol. 40 (3) , e60-e69
Developing a shortened measure of negative thinking for use in patients with heart failure
- 23 March 2011
- Vol. 26 (1) , 9-20
Measurement of Negative Thinking in Patients with Heart Failure: A Critical Review and Analysis
Depression is a significant clinical problem among patients with heart failure (HF). Cognitive therapy is a potential treatment for symptoms of depression in patients with HF. Cognitive therapy focuses on the reduction of negative thinking, a modifiable risk factor for depressive symptoms; however, researchers have not identified the best instrument for measuring negative thinking in patients with HF. The purpose of this paper is to review the state of the science in the measurement of negative thinking in order to provide direction for the measurement of negative thinking in patients with HF. Three of the most widely used instruments for negative thinking were selected for review. The Crandell Cognitions Inventory, Automatic Thoughts Questionnaire, and Cognitive Checklist- Depression all have strong evidence for validity and reliability. The Crandell Cognitions Inventory (CCI) has the best potential for measuring negative thinking in patients with HF. The CCI has the advantages of being developed with a clinical population and captures a wide range of negative thinking content. However, the CCI is lengthy (45 items) and needs to undergo rigorous psychometric testing among patients with HF before it can be recommended for use. Future studies are needed to develop a shortened version of the CCI for use in clinical research and to test the CCI’s reliability and validity for measuring negative thinking in patients with HF.
- 23 March 2011
- Vol. 26 (1) , 9-20
Measurement of Negative Thinking in Patients with Heart Failure: A Critical Review and Analysis
Depression is a significant clinical problem among patients with heart failure (HF). Cognitive therapy is a potential treatment for symptoms of depression in patients with HF. Cognitive therapy focuses on the reduction of negative thinking, a modifiable risk factor for depressive symptoms; however, researchers have not identified the best instrument for measuring negative thinking in patients with HF. The purpose of this paper is to review the state of the science in the measurement of negative thinking in order to provide direction for the measurement of negative thinking in patients with HF. Three of the most widely used instruments for negative thinking were selected for review. The Crandell Cognitions Inventory, Automatic Thoughts Questionnaire, and Cognitive Checklist- Depression all have strong evidence for validity and reliability. The Crandell Cognitions Inventory (CCI) has the best potential for measuring negative thinking in patients with HF. The CCI has the advantages of being developed with a clinical population and captures a wide range of negative thinking content. However, the CCI is lengthy (45 items) and needs to undergo rigorous psychometric testing among patients with HF before it can be recommended for use. Future studies are needed to develop a shortened version of the CCI for use in clinical research and to test the CCI’s reliability and validity for measuring negative thinking in patients with HF.
- 1 January 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 26 (1) , 9-20
Measurement of Negative Thinking in Patients With Heart Failure
Background: Depression is a significant clinical problem among patients with heart failure (HF). Cognitive therapy is a potential treatment for symptoms of depression in patients with HF. Cognitive therapy focuses on the reduction of negative thinking, a modifiable risk factor for depressive symptoms; however, researchers have not identified the best instrument for measuring negative thinking in patients with HF. Objective: The purpose of this article was to review the state of the science in the measurement of negative thinking to provide direction for the measurement of negative thinking in patients with HF. Findings: Three of the most widely used instruments for negative thinking were selected for review. The Crandell Cognitions Inventory (CCI), Automatic Thoughts Questionnaire, and Cognition Checklist-Depression all have strong evidence for validity and reliability. The CCI has the best potential for measuring negative thinking in patients with HF. The CCI has the advantages of being developed with a clinical population and captures a wide range of negative thinking content. However, the CCI is lengthy (45 items) and needs to undergo rigorous psychometric testing among patients with HF before it can be recommended for use. Conclusions: Future studies are needed to develop a shortened version of the CCI for use in clinical research and to test its reliability and validity for measuring negative thinking in patients with HF.
- 1 January 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 26 (1) , 9-20
Measurement of Negative Thinking in Patients With Heart Failure
Background: Depression is a significant clinical problem among patients with heart failure (HF). Cognitive therapy is a potential treatment for symptoms of depression in patients with HF. Cognitive therapy focuses on the reduction of negative thinking, a modifiable risk factor for depressive symptoms; however, researchers have not identified the best instrument for measuring negative thinking in patients with HF. Objective: The purpose of this article was to review the state of the science in the measurement of negative thinking to provide direction for the measurement of negative thinking in patients with HF. Findings: Three of the most widely used instruments for negative thinking were selected for review. The Crandell Cognitions Inventory (CCI), Automatic Thoughts Questionnaire, and Cognition Checklist-Depression all have strong evidence for validity and reliability. The CCI has the best potential for measuring negative thinking in patients with HF. The CCI has the advantages of being developed with a clinical population and captures a wide range of negative thinking content. However, the CCI is lengthy (45 items) and needs to undergo rigorous psychometric testing among patients with HF before it can be recommended for use. Conclusions: Future studies are needed to develop a shortened version of the CCI for use in clinical research and to test its reliability and validity for measuring negative thinking in patients with HF.